New research reveals semaglutide, the active ingredient in Wegovy, shows promise in treating metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease affecting millions. The study indicates significant improvements in liver health among participants, leading to hopes for FDA approval.
Novo Nordisk is partnering with telehealth providers Hims & Hers, Ro, and Life MD to make its weight loss drug Wegovy more accessible. Shares soar as Wegovy becomes readily available.
Hims & Hers Health shares skyrocketed nearly 30% in premarket trading following a groundbreaking partnership with Novo Nordisk to sell the weight loss drug Wegovy. Discover what this means for investors!
In a pivotal court ruling, Judge Mark Pittman denied compounding pharmacies' request for an injunction against the FDA's decision on the semaglutide shortage. This ruling keeps strict timelines for exiting the market, leaving many in the industry concerned.
Pfizer Inc. has decided to stop the development of its obesity pill, danuglipron, after safety concerns emerged from a clinical trial. This move comes as competition heats up with Novo Nordisk and Eli Lilly's successful weight-loss treatments.
Novo Nordisk's diabetes pill Rybelsus has shown significant cardiovascular benefits, reducing the risk of heart-related issues by 14%. This could offer a new, convenient treatment option for many patients.
Discover how a new study suggests that Ozempic, a drug commonly used for diabetes and weight loss, may also help reduce alcohol consumption and cravings in individuals with alcohol-use disorder.
